IL-6R Protein

Interleukin-6 Receptor (IL-6R)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">IL-6R Protein</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Tocilizumab</td>
<td>IL-6R antibody</td>
</tr>
<tr>
<td class="label">Sarilumab</td>
<td>IL-6R antibody</td>
</tr>
<tr>
<td class="label">Satralizumab</td>
<td>IL-6R antibody</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">69 edges</a></td>
</tr>
</table>

Introduction

Interleukin-6 Receptor (IL-6R)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">IL-6R Protein</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Tocilizumab</td>
<td>IL-6R antibody</td>
</tr>
<tr>
<td class="label">Sarilumab</td>
<td>IL-6R antibody</td>
</tr>
<tr>
<td class="label">Satralizumab</td>
<td>IL-6R antibody</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">69 edges</a></td>
</tr>
</table>

Introduction

The Interleukin-6 Receptor (IL-6R) is a critical cytokine receptor that plays a significant role in neuroinflammation, a key pathological feature of neurodegenerative diseases including Alzheimer's Disease (AD) and Parkinson's Disease (PD). [@ilr2023] IL-6R mediates the cellular response to interleukin-6 (IL-6), a pleiotropic cytokine that participates in both acute phase responses and chronic inflammatory processes. [@interleukin2022] The IL-6R signaling pathway has become an important therapeutic target, with tocilizumab (an IL-6R antagonist) showing promise in clinical trials for various neurological conditions. [@tocilizumab2023]

Overview

Interleukin-6 Receptor (IL-6R) is a transmembrane protein encoded by the IL6R gene on chromosome 1q21.3. [@ilr2021] It exists in two forms: a membrane-bound receptor (mIL-6R) of approximately 80 kDa and a soluble receptor (sIL-6R) generated by proteolytic cleavage or alternative splicing. [@soluble2022] The membrane-bound IL-6R is expressed on various cell types including hepatocytes, leukocytes, and certain neuronal populations, while the soluble form can bind IL-6 and trigger signaling in cells that express the signal-transducing subunit gp130 but lack IL-6R itself—a phenomenon known as trans-signaling. [@transsignaling2021]

The IL-6R pathway is particularly relevant to neurodegeneration because chronic neuroinflammation is a hallmark of both AD and PD. [@neuroinflammation2023] Elevated levels of IL-6 and sIL-6R have been detected in the cerebrospinal fluid (CSF) and post-mortem brain tissue of patients with AD and PD, suggesting that dysregulated IL-6 signaling contributes to disease progression. [@csf2022] Genetic studies have also identified IL6R variants as risk factors for AD, further supporting its pathogenic role. [@ilr2021a]

Structure

Extracellular Domain

The IL-6R extracellular domain consists of three distinct regions: [@crystal2020]

Transmembrane and Cytoplasmic Domains

• Transmembrane helix: Single 28-amino acid hydrophobic segment anchors the receptor
• Cytoplasmic tail: Short 82-amino acid domain lacks intrinsic kinase activity but recruits signaling proteins

Soluble IL-6R (sIL-6R)

The soluble form (~55 kDa) retains the extracellular domain and can: [@adammediated2022]

• Bind IL-6 with similar affinity as membrane-bound receptor
• Form a complex with IL-6 that activates gp130-expressing cells
• Be generated by ADAM17-mediated proteolytic shedding (ectodomain shedding)

Normal Physiological Functions

Acute Phase Response

IL-6R signaling is essential for hepatic acute phase protein synthesis: [@acute2021]

• Stimulates production of C-reactive protein (CRP)
• Induces fibrinogen and serum amyloid A
• Modulates body temperature during infection

Immune Cell Differentiation

IL-6R plays crucial roles in immune cell differentiation: [@ilr2023a]

• Th17 differentiation: IL-6R signaling promotes Th17 cell development
• B cell maturation: Supports plasma cell differentiation and antibody production
• Myeloid differentiation: Influences monocyte and macrophage polarization

CNS Development and Function

In the central nervous system, IL-6R signaling contributes to: [@cns2022]

• Neuronal development and survival
• Astrocyte and microglia function
• Synaptic plasticity and modulation

Role in Neurodegenerative Diseases

Alzheimer's Disease

IL-6R signaling contributes to AD pathogenesis through multiple mechanisms: [@ilr2023b]

Neuroinflammation

• Chronic elevation of IL-6 and sIL-6R in AD brain
• Activation of microglia and astrocytes
• Promotion of pro-inflammatory cytokine cascade

Amyloid Pathology

• IL-6R signaling influences APP processing
• May affect amyloid-beta production and aggregation
• Interaction with neuroinflammation amplifies pathology

Tau Pathology

• IL-6 can influence tau phosphorylation
• Neuroinflammation promotes tau spread

Cognitive Decline

Soluble IL-6R levels correlate with cognitive decline in AD patients: [@soluble2022a]

• Higher sIL-6R associated with faster progression
• sIL-6R as potential biomarker for disease staging

Parkinson's Disease

IL-6R plays important roles in PD pathogenesis: [@ilr2023c]

Neuroinflammation

• Elevated IL-6 in CSF and substantia nigra
• Microglial activation via IL-6R signaling
• Contribution to dopaminergic neuron loss

Alpha-synuclein Pathology

• IL-6R may influence alpha-synuclein aggregation
• Neuroinflammation promotes pathology spread

Other Neurodegenerative Diseases

IL-6R involvement extends to: [@ilr2022]

• Multiple sclerosis: IL-6R promotes demyelination
• Amyotrophic lateral sclerosis: Elevated IL-6 correlates with disease progression

Therapeutic Targeting

IL-6R Antagonists

Clinical Trials

Clinical trials of IL-6R blockade in neurological disorders: [@clinical2024]

• Tocilizumab trials: Evaluating cognitive outcomes in AD
• PD trials: Assessing motor and non-motor symptoms
• Safety profile: Generally well-tolerated

Challenges

Biomarker Potential

IL-6R measurements show promise as biomarkers: [@csf2022]

• CSF sIL-6R levels differ between AD and controls
• Combined IL-6/sIL-6R panels improve diagnostic accuracy
• Longitudinal measurements may track disease progression

See Also

• [IL6R Gene](/genes/il6r)
• [Interleukin-6](/proteins/interleukin-6-protein)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Microglia](/cell-types/microglia)

External Links

• [UniProt: P08887](https://www.uniprot.org/uniprot/P08887)
• [GeneCards: IL6R](https://www.genecards.org/cgi-bin/carddisp.pl?gene=IL6R)
• [OMIM: 147920](https://omim.org/entry/147920)

References